These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 24732904

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP, Levitan D, Fleischer AB.
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [Abstract] [Full Text] [Related]

  • 5. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK, Lebwohl M.
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC, Quéreux G, Brocard A, Ballanger F, Khammari A, Nguyen JM, Dréno B.
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [Abstract] [Full Text] [Related]

  • 13. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
    Rupoli S, Canafoglia L, Goteri G, Leoni P, Brandozzi G, Federici I, Micucci G, Giantomassi F, Mozzicafreddo G, Alterini R, Filosa G, Ricotti G, Simonacci M, Scortechini AR, Zizzi A, Pimpinelli N.
    Eur J Dermatol; 2016 Aug; 26(1):13-20. PubMed ID: 26678311
    [Abstract] [Full Text] [Related]

  • 14. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA, Davis MD, el-Azhary RA, McEvoy MT, Gibson LE, Knudsen JM, Kist JM, Pittelkow MR.
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [Abstract] [Full Text] [Related]

  • 15. Topical and oral bexarotene.
    Schadt CR.
    Dermatol Ther; 2013 Jun; 26(5):400-3. PubMed ID: 24099070
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
    Huen AO, Kim EJ.
    Dermatol Clin; 2015 Oct; 33(4):715-29. PubMed ID: 26433844
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Lewis DJ, Huang S, Duvic M.
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
    [Abstract] [Full Text] [Related]

  • 20. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC, Bexarotene Worldwide Study Group.
    J Clin Oncol; 2001 May 01; 19(9):2456-71. PubMed ID: 11331325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.